Comparative Pharmacology
Head-to-head clinical analysis: MIRALAX versus PLENVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRALAX versus PLENVU.
MIRALAX vs PLENVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polyethylene glycol 3350 (PEG 3350) is an osmotic laxative that works by retaining water in the stool through hydrogen bonding, increasing fecal water content and promoting bowel movements.
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
17 g (1 heaping tablespoon) dissolved in 4–8 oz of water, juice, soda, coffee, or tea, administered orally once daily. Maximum duration of use: 7 days.
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500mL, administered orally as a split-dose regimen: first dose (2 sachets in 500mL water) at 6-9 pm on the day before colonoscopy, followed by additional 500mL of clear fluids; second dose (2 sachets in 500mL water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500mL of clear fluids.
None Documented
None Documented
Not applicable; polyethylene glycol 3350 is minimally absorbed and systemic half-life is not clinically relevant.
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
Primarily excreted unchanged in feces (>90% of oral dose); negligible renal elimination (<0.1% recovered in urine).
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Category C
Category C
Osmotic Laxative
Osmotic Laxative